Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ATRA Atara Biotherapeutics Inc
- Stocks
- Healthcare
- NASDAQ: ATRA
Price (delayed)
$6.61
Market cap
$38.73M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$11.41
Enterprise value
$82.09M
Atara Biotherapeutics, Inc.(@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers
Highlights
The EPS has soared by 82% YoY and by 56% from the previous quarter
The net income has soared by 69% YoY and by 36% from the previous quarter
Atara Biotherapeutics's quick ratio has decreased by 45% YoY and by 25% QoQ
The equity has declined by 7% since the previous quarter
Key stats
What are the main financial stats of ATRA
Market
Valuations
Earnings
Shares outstanding
5.86M
Market cap
$38.73M
Enterprise value
$82.09M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.64
Revenue
$128.94M
Gross profit
$107.93M
Operating income
-$83.44M
Net income
-$85.4M
EBIT
-$80.8M
EBITDA
-$63.62M
Free cash flow
-$68.96M
Per share
Balance sheet
Liquidity
EPS
-$11.41
EPS diluted
-$11.41
Free cash flow per share
-$9.21
Book value per share
-$16.89
Revenue per share
$17.22
TBVPS
$14.57
Total assets
$109.1M
Total liabilities
$206.38M
Debt
$68.54M
Equity
-$97.28M
Working capital
-$69.68M
Debt to equity
-0.7
Current ratio
0.48
Quick ratio
0.33
Net debt/EBITDA
-0.68
Margins
Efficiency
Dividend
EBITDA margin
-49.3%
Gross margin
83.7%
Net margin
-66.2%
Operating margin
-64.7%
Return on assets
-63.9%
Return on equity
N/A
Return on invested capital
-457.3%
Return on capital employed
N/A
Return on sales
-62.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ATRA stock price
How has the Atara Biotherapeutics stock price performed over time
Intraday
-1.05%
1 week
-8.95%
1 month
12.99%
1 year
-56.31%
YTD
-50.34%
QTD
11.28%
Financial performance
How have Atara Biotherapeutics's revenue and profit performed over time
Revenue
$128.94M
Gross profit
$107.93M
Operating income
-$83.44M
Net income
-$85.4M
Gross margin
83.7%
Net margin
-66.2%
The net margin has soared by 98% YoY and by 50% from the previous quarter
ATRA's operating margin has surged by 98% year-on-year and by 50% since the previous quarter
The operating income has soared by 70% YoY and by 36% from the previous quarter
The net income has soared by 69% YoY and by 36% from the previous quarter
Price vs fundamentals
How does ATRA's price correlate with its fundamentals
Growth
What is Atara Biotherapeutics's growth rate over time
Valuation
What is Atara Biotherapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
0.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.64
The EPS has soared by 82% YoY and by 56% from the previous quarter
The equity has declined by 7% since the previous quarter
ATRA's P/S is 99% below its 5-year quarterly average of 56.4 and 71% below its last 4 quarters average of 1.3
Atara Biotherapeutics's revenue has increased by 28% QoQ
Efficiency
How efficient is Atara Biotherapeutics business performance
Atara Biotherapeutics's return on invested capital has shrunk by 189% YoY and by 16% QoQ
The ROS has soared by 98% YoY and by 51% from the previous quarter
The company's return on assets rose by 48% YoY and by 29% QoQ
Dividends
What is ATRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ATRA.
Financial health
How did Atara Biotherapeutics financials performed over time
The total assets is 47% less than the total liabilities
Atara Biotherapeutics's quick ratio has decreased by 45% YoY and by 25% QoQ
The total assets has contracted by 34% YoY and by 24% from the previous quarter
The debt is 170% more than the equity
The debt has decreased by 15% YoY and by 6% from the previous quarter
ATRA's debt to equity is up by 14% year-on-year and by 13% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.